CDKN2A and mesothelioma: A recent study indicated that Nf2; Cdkn2a-deficient mouse mesothelioma cells showed less malignant phenotypes with PAK2 loss, suggesting that anti-PAK drugs may be promising for mesothelioma treatment (Sementino et al., 2022).